FDA grants full ap­proval to Tra­vere’s Filspari for IgAN 

Tra­vere Ther­a­peu­tics won full ap­proval for Filspari, which treats a rare au­toim­mune dis­ease that af­fects the kid­neys.

Filspari, al­so known as sparsen­tan, re­ceived an ac­cel­er­at­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER